1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,233 | 0,281 | 11:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08:30 | AcouSort AB: AcouSort receives new order from Moeller Medical for continued product development | 58 | GlobeNewswire (Europe) | AcouSort AB has received a new order from German medical technology company Moeller Medical GmbH with a total value of EUR 13,000. The order covers further development and delivery of AcouSort separation... ► Artikel lesen | |
| 22.10. | AcouSort AB: Bulletin from the Extraordinary General Meeting of AcouSort AB (publ) | 157 | GlobeNewswire (Europe) | AcouSort AB (publ) (the "Company") held an Extraordinary General Meeting (the "EGM") on 22 October 2026 in Lund. The EGM resolved, in accordance with the proposal of the Board of Directors, to approve... ► Artikel lesen | |
| 01.10. | AcouSort AB: AcouSort AB enters into strategic OEM supply agreement with Calyrex Biosystems Inc. and Marketing agreement with Intelmetis Inc. combined with a SEK 15m convertible note financing | 180 | GlobeNewswire (Europe) | AcouSort AB (publ) ("AcouSort" or the "Company") today announces that it has entered into an OEM supply and development agreement (the "OEM Supply Agreement") and a marketing consulting agreement (the... ► Artikel lesen | |
| 26.08. | AcouSort AB Q2 Loss Increases | 2 | RTTNews | ||
| ACOUSORT Aktie jetzt für 0€ handeln | |||||
| 26.08. | AcouSort AB: AcouSort AB - Interim Report for the period January - June 2026 | 182 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037
April-June 2026 for the Group• Net sales amounted to TSEK 2,116 (1,551)• Result before tax amounted... ► Artikel lesen | |
| 27.05. | AcouSort AB: AcouSort AB - Interim Report for the period January - March 2026 | 213 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
First quarter 2026 for the GroupNet sales amounted to TSEK 2,147 (1,595)Result before tax amounted... ► Artikel lesen | |
| 10.03. | AcouSort AB: AcouSort receives prepayment of royalties | 349 | GlobeNewswire (Europe) | AcouSort AB today announced the signing of an amendment to its license and distribution agreement with the leading blood-gas analyzer company, Werfen. Under the amendment, Werfen will prepay minimum... ► Artikel lesen | |
| 25.02. | AcouSort AB: Year end report for AcouSort AB 1 January - 31 December 2025 | 257 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.October - December 2025 for the GroupNet sales amounted to TSEK 2,459 (1,221)Result before tax... ► Artikel lesen | |
| 19.12.25 | AcouSort AB: AcouSort and MFX enter a collaboration to streamline future cell therapy manufacturing | 1.236 | GlobeNewswire (Europe) | AcouSort AB today announced it has entered a collaboration with MFX, a UK-based developer of next-generation scalable bioreactor platforms, to evaluate if AcouSort's technology can be paired with MFX's... ► Artikel lesen | |
| 15.12.25 | AcouSort AB: Stefan Blomsterberg elected new Chairman of the Board of AcouSort | 314 | GlobeNewswire (Europe) | AcouSort AB today announced that Stefan Blomsterberg has been appointed new Chairman of the Board, effective January 1, 2026.
Stefan Blomsterberg currently holds the position as CEO of CELLINK Bioprinting... ► Artikel lesen | |
| 26.11.25 | AcouSort AB: AcouSort AB - Interim Report for the period January - September 2025 | 277 | GlobeNewswire (Europe) | The "Company" or "AcouSort" refers to AcouSort AB (publ) with corporate registration number 556824-1037.
July - September 2025 for the GroupNet sales amounted to TSEK 1,248 (1,198)Result before tax... ► Artikel lesen | |
| 19.11.25 | AcouSort AB: AcouSort and Danish SeeQ Diagnostics sign technology evaluation agreement | 472 | GlobeNewswire (Europe) | AcouSort AB today announced it has signed a technology evaluation agreement with the Danish diagnostics company SeeQ Diagnostics concerning the evaluation of AcouSort's blood/plasma separation technology... ► Artikel lesen |
12 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVONESIS | 59,60 | +1,09 % | Diese Branche hofft: Der nächste Milliarden-Boom nach den Abnehmspritzen? | © Foto: Thomas Rasmussen - picture alliance / Gonzales PhotoDer Erfolg von Wegovy und Ozempic verändert ganze Branchen. Nun wittern Hersteller von Nahrungsergänzungsmitteln eine Milliardenchance. Ein... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 6,894 | +2,25 % | BioCryst Pharmaceuticals (NDQ:BCRX): The Market Is Valuing ORLADEYO, But Is Navenibart The Real Prize? | ||
| SARTORIUS STEDIM BIOTECH | 223,60 | +0,99 % | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| ADMA BIOLOGICS | 12,660 | -0,08 % | ADMA Biologics hits 10-month high as Asceniv drives Q3 beat | ||
| CRESCENT BIOPHARMA | 11,800 | +3,51 % | Crescent Bio auf Guggenheim Healthcare Conference: Breiter Immunonkologie-Markt im Visier | ||
| PEPGEN | 4,620 | +0,22 % | PepGen soars on promising early data for muscular dystrophy drug | ||
| PRAXIS PRECISION MEDICINES | 337,27 | 0,00 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| DISC MEDICINE | 84,77 | +0,15 % | Disc Medicine auf der Guggenheim-Konferenz: Finanzstarker Vorstoß in die Vermarktungsphase | ||
| ARCUTIS BIOTHERAPEUTICS | 27,385 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| DYNE THERAPEUTICS | 17,920 | 0,00 % | Dyne Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 15,480 | 0,00 % | Tango Therapeutics, Inc.; Erasca, Inc.: Tango and Erasca Initiate Phase 1/2 Study of Oral PRMT5 Inhibitor Vopimetostat in Combination with Pan-RAS Molecular Glue ERAS-0015 | ||
| EDGEWISE THERAPEUTICS | 46,570 | +0,09 % | Edgewise Therapeutics Announces Productive End-of-Phase 2 Meeting with FDA for EDG-7500 in HCM; Phase 3 Protocol Features Tolerability-Based Dose Escalation Without Safety Echo Monitoring | - Following the End-of-Phase 2 meeting, Edgewise has submitted the STRATUS-HCM Phase 3 protocol with dose escalation guided by investigator assessment of tolerability -- STRATUS-HCM includes two independent... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,600 | 0,00 % | Cogent Biosciences auf Guggenheim-Konferenz: Marktstart rückt näher | ||
| TANGO THERAPEUTICS | 24,280 | -0,08 % | Jefferies raises Tango Therapeutics stock price target on trial data | ||
| ABSCI | 9,970 | 0,00 % | Absci auf der Guggenheim-Gesundheitskonferenz: Eigene Pipeline rückt in den Fokus |
ACOUSORT AB gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 0,252 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACOUSORT AB finden Sie auf Wallstreet Online.